TrialESMO open2024

Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial.

T K Choueiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.